Sarah Boyce - 15 Aug 2022 Form 4 Insider Report for Avidity Biosciences, Inc. (RNA)

Role
President and CEO, Director
Signature
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
Issuer symbol
RNA
Transactions as of
15 Aug 2022
Net transactions value
-$2,123
Form type
4
Filing time
17 Aug 2022, 21:40:20 UTC
Previous filing
13 Jun 2022
Next filing
26 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNA Common Stock Options Exercise $124 +100 $1.24* 100 15 Aug 2022 Direct F1
transaction RNA Common Stock Sale $2,247 -100 -100% $22.47 0 15 Aug 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RNA Stock Option (Right to Buy) Options Exercise $0 -100 -0.01% $0.000000 1,196,915 15 Aug 2022 Common Stock 100 $1.24 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.